Joo Sang Lee

Joo Sang Lee

Auto-generated profile, based on publicly available information

Joo Sang Lee

Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Republic of Korea.

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMan Hsin Hung
Man Hsin Hung
JLJoo Sang Lee
Joo Sang Lee
CMChi Ma
Chi Ma
LDLaurence P. Diggs
Laurence P. Diggs
SHSophia Heinrich
Sophia Heinrich
XWXin Wei Wang
Xin Wei Wang
T-cell exhaustion denotes a hypofunctional state of T lymphocytes commonly found in cancer, but how tumor cells drive T-cell exhaustion remains elusive. Here, we find T-cell exhaustion linked to overall survival in 675 hepatocellular carcinoma (HCC) patients with diverse ethnicities and etiologies. Integrative omics analyses uncover oncogenic reprograming of HCC methionine recycling with elevated 5-methylthioadenosine (MTA) and S-adenosylmethionine (SAM) to be tightly linked to T-cell exhaustion. SAM and MTA induce T-cell dysfunction in vitro. Moreover, CRISPR-Cas9-mediated deletion of MAT2A, a key SAM producing enzyme, results in an inhibition of T-cell dysfunction and HCC growth in mice. Thus, reprogramming of tumor methionine metabolism may be a viable therapeutic strategy to improve HCC immunity.

1 November 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
JLJoo Sang Lee
Joo Sang Lee
EREytan Ruppin
Eytan Ruppin
Targeting programmed death 1 (PD-1) or its ligand (PD-L1) offers significant clinical benefits in many cancers. One emerging biomarker of response to anti–PD-1/PD-L1 therapy is the tumor mutational burden,1,2 which quantifies the number of somatic mutations in the tumor. The mutational burden has recently been shown by Yarchoan et al3 to strongly correlate with the response rate for anti–PD-1/PD-L1 therapies across multiple cancer types. However, tumors containing comparably high mutational burden may exhibit variable responses,4-6 suggesting that additional factors may contribute to anti–PD-1/PD-L1 response. Herein we systematically study this hypothesis, aiming to identify the most important additional factor(s) that contribute to response prediction. To this end we analyze whole-exome sequencing and RNA sequencing data of pretreated samples from 21 different cancer types in the Cancer Genome Atlas (TCGA). We find that a trivariate model composed of tumor mutational burden, estimated CD8+ T-cell abundance (eCD8T), and fraction of high PD-1 messenger RNA expression samples (fPD1) markedly enhances the prediction of the response to anti–PD-1/PD-L1 therapy across different cancer types.

1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
XFXiaodong Feng
Xiaodong Feng
NANadia Arang
Nadia Arang
DRDamiano Cosimo Rigiracciolo
Damiano Cosimo Rigiracciolo
JLJoo Sang Lee
Joo Sang Lee
HYHuwate Yeerna
Huwate Yeerna
JGJ.Silvio Gutkind
J.Silvio Gutkind

14 April 2021 in Cell
Verified
Journal Article
Closed access
JLJoo Sang Lee
Joo Sang Lee
NNNishanth Ulhas Nair
Nishanth Ulhas Nair
GDGal Dinstag
Gal Dinstag
LCLesley Chapman
Lesley Chapman
YCYoungmin Chung
Youngmin Chung
EREytan Ruppin
Eytan Ruppin

27 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ANAshish Noronha
Ashish Noronha
NNNishanth Belugali Nataraj
Nishanth Belugali Nataraj
JLJoo Sang Lee
Joo Sang Lee
BZBenny Zhitomirsky
Benny Zhitomirsky
YOYaara Oren
Yaara Oren
YYYosef Yarden
Yosef Yarden
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether the treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells and in EGFRi-treated patients presenting residual disease, we observed upregulation of GAS6, whereas ablation of GAS6's receptor, AXL, eradicated resistance. Reciprocally, AXL overexpression enhanced DTP survival and accelerated the emergence of T790M, an EGFR mutation typical to resistant cells. Mechanistically, AXL induces low-fidelity DNA polymerases and activates their organizer, RAD18, by promoting neddylation. Metabolomics uncovered another hypermutator, AXL-driven activation of MYC, and increased purine synthesis that is unbalanced by pyrimidines. Aligning anti-AXL combination treatments with the transition from DTPs to resistant cells cured patient-derived xenografts. Hence, similar to bacteria, tumors tolerate therapy by engaging pharmacologically targetable endogenous mutators. Significance: EGFR-mutant lung cancers treated with kinase inhibitors often evolve resistance due to secondary mutations. We report that in similarity to the bacterial SOS response stimulated by antibiotics, endogenous mutators are activated in drug-treated cells, and this heralds tolerance. Blocking the process prevented resistance in xenograft models, which offers new treatment strategies. This article is highlighted in the In This Issue feature, p. 2483

31 August 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
RKRom Keshet
Rom Keshet
JLJoo Sang Lee
Joo Sang Lee
LALital Adler
Lital Adler
MImuhammed iraqi
muhammed iraqi
YAYarden Ariav
Yarden Ariav
AEAyelet Erez
Ayelet Erez